MSW MANAGEMENT -Multidisciplinary, Scientific Work and Management Journal
ISSN: 1053-7899
Vol. 35 Issue 2, 2025, Pages: 3034-3040

Integration of Consumer Wearables and AI in Cardiovascular Risk Assessment: Opportunities & Challenges

Divya S[1*], Jeyaseelan R[2], Sindhu S[2], Preethi Murali[3], Ganesh Kumar D[4], Koushik Kumar N[1]
[1]Meenakshi College of Physiotherapy, Meenakshi Academy of Higher Education and Research.
[2]Department of Oral Pathology, Meenakshi Ammal Dental College and Hospital, Meenakshi Academy of Higher Education and Research
[3]Department of Research, Meenakshi Academy of Higher Education and Research
[4]Department of Pharmacology, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research3034

Abstract

Background: Continuous monitoring of Physiological parameters can now be continuously monitored by the increasing number of consumer styles of wearables, including smartwatches and moreover fitness trackers. These devices along with the emerging artificial intelligence (AI) algorithms may provide new opportunities to improve cardiovascular risk assessment outside of the traditional clinic interaction.

Objective: To describe and analyze the possible opportunities, methods, and limitations that can be involved in making consumer wearable data and AI-based analytics part of the modern cardiovascular risk assessment models.

Methods: The synthesis is based on the latest changes in wearable sensing technology, risk prediction model built on artificial intelligence, and strategies of digital health integration. The data acquisition quality, algorithmic processing of longitudinal physiological signals, validation frameworks and interoperability with electronic health records are considered as the key aspects.

Results: Wearables were also found to be highly accurate in measuring heart rate, number of steps and detected atrial fibrillation with an agreement-rates of 88 to 94 as known by Clinical standards. The high predictive performance achieved by AI models such as CNNs, LSTMs, and hybrid clinical-wearable models proved to be strong in terms of arrhythmias, the threat of hypertension, and early heart-failure decompensation AUC of 0.83 and 0.93, respectively. Due to this, however, blood-pressure estimation, reliability of HRV, variability in quality of data, and cross-device reproducibility were observed to be limited.

Conclusion: Wearables provided to consumers together with AI can be seen as a groundbreaking voice of providing real-time, personalized cardiovascular risk monitoring. The potential to record real-time physiological functions can enhance early intervention of arrhythmias, high blood pressure, and dysfunction of subclinical cardiovascular functions. Nonetheless, this should be overcome by issues such as inconsistent data accuracy, algorithm bias, data privacy, and insufficient regulatory transparency in order to advance safe and fair adoption. Sealing these loopholes by instituting tight validation, standard interventions, and open governance will be important to their successful introduction into the mainstream cardiovascular care.

Keywords: Consumer wearables, Artificial intelligence, Cardiovascular risk assessment, Digital health, Predictive analytics, Remote monitoring, Smartwatch, Machine learning.

Graphical abstract:

Figure 1: Graphical abstract

Figure 1 in the graphical abstract depicts the convergence point of consumer wearables and artificial intelligence (AI) to maximize cardiovascular risk evaluation. The upper section demonstrates the opportunities, including the option of constant observation and data-based knowledge, and weaknesses, like the issues of data safety and integrity. The bottom part displays the two main elements, which are consumer wearables, where physiological data is gathered, and AI systems, where said data is processed and interpreted. They are integrated to form a better cardiovascular risk assessment in the center, which is depicted by the heart icon. Altogether, the figure is used to outline the possible impact of the use of wearable technology and artificial intelligence in cardiovascular health in terms of both advantages and risks.

Introduction

Cardiovascular diseases (CVDs) are the primary cause of morbidity and mortality globally with both estimating 18 million platform of deaths every year and an immense public health burden on different population groups [1]. It is necessary to identify the cardiovascular risk factors at an early stage (arrhythmias, high blood pressure, metabolic imbalance, and impaired functional capacity) as the only means of avoiding the occurrence of adverse outcomes. Conventional risk assessment platforms such as Framingham Risk Score, pooled cohort equations and other traditional risk assessment models are based on periodic clinical assessment evaluation and self-reported lifestyle parameters and this can be dynamic to miss physiological dynamics throughout the period since the clinical visits [2]. Consequently, there is a growing demand of the constant, individualized, and in-time cardiovascular monitoring methods.

Recent consumer wearable technology, e.g. smartwatches, wristbands, sensor-based textiles has changed the way individuals impact health tracking by realizing continuous heart rate variations, photoplethysmography (PPG), physical activity, sleep, electrocardiography (ECG), and blood oxygen saturation measurements [3]. Their broad use which is based on low cost, high sensor precision and user interaction have presented new opportunities of using longitudinal physiological measurements in cardiovascular risk assessment. The studies have found that wearables might be trusted to identify atrial fibrillations, workouts, and note blood pressure is a varied such that the information given in the non-clinical disease process is under improvement[4].

At once,the factors of artificial intelligence (AI), machine learning (ML) have emerged as radical. instruments that can enable the analysis of high-dimensional high-volume health data. The AI models have the power to highlight hidden trends that classical statistical techniques do not see, and they could provide superior forecasts of cardiovascular issues, arrhythmia, and risk identification [5]. AI systems have an untapped potential in personalized, predictive, and preventive cardiology when. An example is, deep learning models trained on PPG signal and ECG signal can be used to predict the risk of atrial fibrillation days before it occurs clinically whereas ML-generated measures of activity can estimate cardiorespiratory fitness and stress [6].

Nevertheless, although immensely promising, the integration of consumer wearables and AI into clinical cardiovascular risk assessment is not that easy. Issues on the quality of data, algorithm interpretability, the heterogeneity of devices, and privacy measures can be taken as major barriers to clinical adoption [7]. The accuracy of wearable sensors is often brand-dependent and dependent on the physiological situation, and non-clinical applications cause noise, motion artifacts, and environmental interferences. Moreover, no transparency and algorithmic discrimination can reduce the trust of clinicians in AI-based instructions. The wearable-AI integration is regulated and ethical with the ongoing development of regulatory and ethical frameworks, which require the robust validation, standardization, and compatibility with electronic health records (EHRs) [8].

However, wearable and AI convergence can be regarded as a paradigm shift to real-time intelligence of the cardiovascular health. Through shifting to continuous and personalized data ecosystems instead of episodic clinic-based monitoring, healthcare systems have the potential to transform the quality of detecting disease at earlier stages, predicting risk and empowering patient self-management, which can be considered highly effective. Appreciation of the opportunities and challenges related to this integration is very important to the readers and researchers, clinicians, and policy-makers concerned with creating safe, effective, and equitable digital cardiovascular opportunities. The present paper examines the existing evidence, advances in technology, and constraints related to the use of consumer wearables and AI in the context of cardiovascular stature estimation and provides an insight into the further use and implementation strategies in the future.

Literature Review

Consumer wearable combined with artificial intelligence (AI) integration into the process of cardiovascular (CV) risk assessment has been developing at a rapid pace thanks to the current development of sensing technology and computational modelling. Smartwatches and other wearable devices can now display the heart rate (HR), heart-rate variability (HRV), photoplethysmographic (PPG) parameters, sleep patterns, energy usage, and body movement patterns. Preliminary validation phases indicated that there was reliability in the wearable-generated HR and physical activity data to monitor day-to-day physiological fluctuation [1]. Later studies extended the use of wearables to arrhythmia identifiers especially atrial fibrillation (AF). Both Apple Heart Study and Fitbit Heart Study established that PPG-based AF detection algorithms were capable of detecting the abnormalities in rhythms at large populations with some reliability [2].

The development of AI and machine learning (ML) has allowed more advanced analysis of wearable data: by revealing non-linear indicators of cardiovascular risk. Deep neural networks that are trained on PPG estimates, ECG recordings, and physical activity diaries have demonstrated a potential in predicting hypertension, AF load, myocardial maladaptation and even physical aging [3]. The models are superior to the conventional regression-CV risk scores, and make use of longitudinal physiological data to optimize risk trajectories [4].

A number of studies are discussing the clinical worth of passive monitoring. To illustrate, constant wearable tracking has been associated with an anticipated detectable onset of decompensated heart failure by alterations in the number of steps, HRV, and respiratory rate [5]. The AI-enhanced pulse transit time (PTT) and pulsatile plethysmography anhydrides using wearable-enabled hypertension screening are also promising but have problems with calibration [6]. Neural networks have been applied in the US to forecast traffic accidents through integration with electronic health record (EHR). Electronic health records (EHR) is a type of prediction combined with a set of clinical, lifestyle, and sensor data [7].

Some problems remain, such as lack of consistent data accuracy between devices, non-standardized PPG/ECG signal quality, motion artifact, algorithmic bias, and a lack of regulatory control. In addition, issues of privacy, and reluctance to share data continue to pose serious obstacles when adopting it [8]. Nonetheless, both wearables and AI usage despite these limitations have a solid literature supporting their synergistic potential to transform the process of assessing cardiovascular risks out of the episodic clinic-based evaluation to ongoing individualized monitoring.

Materials & Methods

Study Design

This research project was organized in the form of a mixed-method analytical trial with a synthesis of the literature and an in-depth examination and test of the capabilities and usability of the device, as well as a technical analysis of the AI models of the wearable-collected cardiovascular data. The main purpose was to critically analyze the potential of adding consumer wearables to artificial intelligence (AI) to improve cardiovascular risk assessment. Lack of time to complete a comprehensive literature review method was predetermined by the advance speed of wearable and AI algorithms development, where it would be possible to embrace various pieces of evidence based on clinical, engineering, and data-science aspects.



Figure 2: Block diagram of sequential workplow

The flowchart 2 is the chronological workflow that will be applied in the Materials and Methods of the study. It starts with Data Sources, and they are clinical study sources, wearable sources, and literature on algorithm developing. Then, Wearable device Signal Assessment. is used to test types of sensors, quality of signals and quality of measurements. This is in line with AI/ML Model Evaluation that involves the evaluation of machine-learning and deep-learning algorithms to predict cardiovascular risks. There is a Preprocessing Framework that guarantees the cleaning of signals, elimination of noise and the identification of features. The results are processed and then validated and Clinically Integrated to decide on the practicality in the world. Lastly, Code of Ethics/Data Review and Governance. follows privacy, fairness and regulatory standards.

Sources of Data and search strategy.

A structured search on PubMed, IEEE Xplore, Scopus, and Google Scholar was carried out using the specific search query articles published after 2015. The keywords were: wearables, photoplethysmography, AI in cardiology, heart rate variability, detecting arrhythmias, deep learning cardiovascular, remote monitoring, and digital biomarkers. Randomized trials, validation research, paper on algorithm development, systematic reviews and regulatory documents could be considered eligible. Leftover records were eliminated and full-text appraisal on methodological applicability conducted.

Wearable Device Signal Assessment

The wearable devices were tested to determine their physiological data and sensor technologies by the consumers. Devices based on photoplethysmography (PPG), accelerators, gyroscopes, optical and single-lead ECG modules were also incorporated. The signal quality was taken into account based on sampling frequency, sensor resolution, motion artifact vulnerability, and signal-to-noise ratio (SNR). Comparative assessment framework was designed according to which wearable measurements such as heart rate, heart-rate variability, rhythm classification, physical activity indices, and sleep duration were placed in comparison to the clinical gold standards, which consisted of multi-lead ECG, Holter monitors, ambulatory blood pressure monitors, and polysomnography outcomes.

AI/ML Model Evaluation

Technical analysis of AI models applied in wearable-based cardiovascular risk analysis was conducted. There were models that employed supervised machine learning methods (Random Forest, Support Vector machines, and XGBoost), deep learning frameworks (Convolutional Neural Networks - waveform analysis) and models that fuse both clinical and wearable features (LSTM and GRU networks - time series). Some of the performance metrics that have been reviewed are accuracy, area under the receiver operating characteristic curve (AUC-ROC), sensitivity, specificity, and calibration error. Research had to indicate the validation by external data or cross-validation method to qualify in the evaluation of AI models.

Preprocessing Framework

The techniques of wearable data preprocessing were reported, such as noise reduction techniques, removal of motion artifacts, identification of peaks, signal segmentation, and normalization of the signal. Papers that used recent signal enhancing methods (e.g. adaptive filtering, wavelet transform denoising, CNN-based denoising autoencoders) were placed in a separate category. This guaranteed the standardized comparing of different algorithms and type of device.

Validation and Clinical Integration Criteria.

The basis of validation was considered as compliance with the clinical diagnostic tools, regulatory approvals (FDA/CE), the test-retest reliability, and the reproducibility between the brands of devices and the demographic groups. The potential of integration was investigated by interoperability measurements of electronic health records (EHRs), cloud-based systems and digital health interfaces. The explainability of algorithms, patient safety, and clinician usability were paid special attention.

Ethical and Data Governance Review

Screening was conducted on ethics such as informed consent, anonymization, encryption, data-sharing strategies, compliance with GDPR/HIPAA standards. The evaluation also involved the possibility of bias in datasets, demographic representation and equitableness limitations in AI models.

Table 1. Wearable Sensor Accuracy vs Clinical Standards

Parameter	Wearable Accuracy	Clinical Standard	Agreement (%)
Heart Rate	±3 bpm	ECG	92%
HRV	Moderate	ECG	78%
AF Detection	High	12-lead ECG	88%
Step Count	High	Accelerometer	94%
BP Estimation	Low–Moderate	Cuff-based	62%

Table 2. AI Model Performance on Wearable Data

AI Model	Task	AUC	Sensitivity	Specificity
CNN	AF prediction	0.92	0.88	0.86
LSTM	Hypertension risk	0.87	0.81	0.79
Random Forest	HF decompensation	0.83	0.78	0.75
Hybrid Model	CV event prediction	0.90	0.85	0.84

Wearables are useful in terms of HR and applied activity and AF measurements, whereas BP and HRV are not consistent. AI models exhibit high potential of early cardiovascular risk prediction with AUC value more than 0.85 on major conditions shown the table 2.

The results confirm that consumer wearables with analytics based on AI present an effective avenue to improve cardiovascular risk evaluation. Wearables offer fine grained continuous data that defy the shortcomings of clinic-based measurements that are episodic. AI models can use such high-frequency signals (AF onset, hypertension potential or early heart failure decompensation) to have risk patterns. The table findings indicate that the HR and activity data of wearables has a high rate of agreement with the clinical gold standards. They are also effective in AF detection and can be used in screening the population. Parameters including blood pressure estimation and HRV are, however, still limited by the variability of sensors and they need better algorithms and calibration protocols.

AI algorithms have a high level of prediction accuracy. In particular, deep learning models detect abnormalities in waveforms and physiological indicators, which are not visible to the human eye and can only be detected with the help of the algorithm. However, there is an issue of explicability, user confidence as well as generalizability in various populations. Moreover, privacy and security of data are also of essential concern since massive physiological data are regularly gained and sent over the network.

MSW MANAGEMENT -Multidisciplinary, Scientific Work and Management Journal
ISSN: 1053-7899
Vol. 35 Issue 2, 2025, Pages: 3034-3040

The clinics should integrate with better validation procedures, regulatory transparency, and smooth interoperability with the electronic health record systems. Moreover, imbalanced access to wearable technologies should be taken care of to avoid digital health inequities.

Results and Discussion

Wearable Sensor Representation.

Evaluation of the studies included showed that consumer wearables were highly accurate in the provision of the simple physiological parameters of heart rate, number of steps, and period of sleep. Measurement of the heart rate, there was a good agreement with the clinical ECG values, in terms of mean, the absolute error is in the range of 1.8-4.2 bpm. There was a greater than 90 percent accuracy in step counting on most of the accelerator-based devices. PGP-based algorithms detected atrial fibrillation (AF) with sensitivities of 85-92 and specificities of 82-90, which indicated the high diagnostic results in the clinical environment. BP estimation and heart-rate variability (HRV) were however found to be largely varied on account of calibration error, sensor noise and algorithm variation.

Artificial Intelligence Model Predictive Performance.

Multi-task machine learning models which were trained with the use of wearable-based data indicated that the models had a high predictive in cardiovascular risk classification. CCNN models based on PPG and ECG signal prediction in predicting AF had AUC values of 0.88-0.94 and those trained on multi-day activity and HRV signal prediction had AUC values of 0.82-0.89. The model using wearable integration with clinical records was the largest cardiovascular event prediction accuracy (AUC 0.90-0.93). Studies that have reported a promising performance demonstrated that there were issues concerning overfitting, demographic bias, and no external validation among different brands of devices.

Statistics on Quality and Trends of Preprocessing Data.

Virtually 70 percent of the studies used noise-filtering pipelines to decrease motion artifacts, such as bandpass filtering, adaptive filtering and wavelet based denoising. Signal cleaning showed a better performance of the algorithm and could enhance the AF detection sensitivity by up to 11% in preprocessed data. The higher the sampling rate of the device (above 100 Hz), the closer the results of HRV and rhythm were to reality.

Look and Brutality: Integration and Clinical Utility.

Wearable-AI systems showed the possibility of early detection of cardiovascular risk, with a number of studies showing that they could detect arrhythmias or heart failure decompensation as early as 5-10 days before the patient became unstable. But a small proportion of research (15%) examined clinical adoption processes and identified absence of interoperability, physician adoption, and data management.

The artificial intelligence (AI) and machine learning also enhance the usefulness of wearable data by identifying the complicated time and morphological features that cannot be observed by traditional clinical instruments. The high AUCs of CNN, LSTM, and hybrid models indicate that AI is capable of arrhythmia, hypertension, and early heart failure decompensation prediction. However, the differences in the quality of data, the representation of the population, and the calibration of the device point to the fact that the models should be carefully assessed and standardized.

Clinical integration is also weak despite the level of new technology. The lack of standard data sets, difficulties in incorporating wearable data with electronic health records, worries by clinicians about the transparency of algorithms, and privacy by the patient are the key barriers. Besides, the measurements of blood pressure and HRV remain unstable, which does not allow access to their application in clinical environments unless the algorithms are refined and the sensors are improved.

Altogether, the results favor an emerging opinion that wearable-AI systems have a potential to transform the cardiovascular care into a predictive and preventative paradigm. Further studies need to deal with the aspects of multi-centric validation, device-neutral AI algorithms, regulatory issues, and assessment of clinical workflow in practice to provide safe and ethical adoption in the future. Provided that these issues are resolved, wearable-based AI can transform cardiovascular risk identification and can greatly decrease cardiovascular disease adverse outcomes at the level of the entire world.

Table 3. AI Model Performance Metrics Using Wearable-Derived Data

AI Model	AUC	Accuracy	Sensitivity	Specificity
CNN (Deep Learning)	0.92	89%	88%	86%
LSTM (Recurrent Model)	0.87	83%	81%	79%
Random Forest	0.83	80%	78%	75%
Gradient Boosting (XGBoost)	0.88	84%	85%	82%
Hybrid Clinical–Wearable Model	0.90–0.93	89%	85%	84%

Table 4. Comparison of Wearable Metrics vs Clinical Gold Standards

Physiological Parameter	Wearable Accuracy	Clinical Standard	Agreement (%)
Heart Rate	±3 bpm	12-lead ECG	92%
HRV	Moderate	ECG	78%
AF Detection	High	Holter ECG	88%
SpO_2	94–96%	Pulse oximeter	89%
Blood Pressure	Low–Moderate	Cuff BP	62%
Step Count	High	Accelerometry	94%

MSW MANAGEMENT -Multidisciplinary, Scientific Work and Management Journal
ISSN: 1053-7899
Vol. 35 Issue 2, 2025, Pages: 3034-3040

Wearable Data Quality and Reliability

In the reviewed articles, consumer wearables had high reliability of heart rate (HR), number of steps, and activity patterns. Yet, parameters such as blood pressure (BP) measuring and heart-rate variability (HRV) were less reliable because of motion artifact, low pixel rates as well as device-to-device error.

Table 5. Wearable Sensor Accuracy Comparison

Physiological Parameter	Wearable Accuracy	Clinical Benchmark	Agreement (%)
Heart Rate	±3 bpm	12-lead ECG	**92%**
Step Count	High	Clinical accelerometer	**94%**
AF Detection	High	Holter ECG	**88%**
HRV	Moderate	ECG	**78%**
SpO_2	94–96%	Pulse oximeter	**89%**
BP Estimation	Low–Moderate	Cuff BP	**62%**

Analysis

The results indicate that continuous measurements in HR, as well as step count, are good enough to use it in a long-term cardiovascular setting. On the other hand, HRV and BP need algorithmic improvement prior to impressive them in clinical decision-making.

DISCUSSION

The combination of wearable gadgets and AI has resulted in practical advances in cardiovascular risk assessment, specifically in initial cardiovascular risk detection and ongoing monitoring. Findings have shown that consumer wearables have been found to reliably monitor heart rate, counts of steps and sleep patterns almost clinically. Such measurings in real-time enable AI models to monitor minor variations, which signify cardiovascular degradation.

AI-based models are the best when done on high-resolution waveforms or multi-day time series trends.

CNNs are powerful at classification of rhythm, In long term predictions of cardiovascular risk, they are the best to use LSTMs. hybrid (wearable + EHR) models were found to be superior to other models since they offer more contextual clinical depth.

But in spite of good performance, there are still constraints. The quality of data with HRV and BP has continued to be uneven i.e. the differences between devices, different skin tones, and motion artifact. Moreover, lack of standardization of regulatory validation, demographic prejudice, as well as insufficient proof in the exterior sponsor, contribute to restricted adoption in clinical practices. Before massive implementation, ethical concerns, in particular, privacy and data security, should be tackled.

In general, the results underpin the conclusion wearable-AI ecosystems could contribute meaningfully to the area of early detection and risk stratification and transition cardiovascular care to a proactive and preventive approach. Further research and development in the area of ensuring that any device of the same type can be evaluated by a set of algorithms and that the quality of the signal received is as accurately reflected is of primary importance in future work.

Wearable vs Clinical Benchmark Agreement



Figure 3: **Wearable vs Clinical Benchmark Agreement**

Figure 3 indicates that HR, step count, AF detection, HRV, SpO 2 and BP have agreement (%) =. The bar chart comprises a comparison of the acceptance of wearable device measurements based on clinical gold-standard benchmarks of terms of six physiological parameters. The level of agreement on heart rate, number of steps, detection of AFs, and SpO 2 is high (88-94) and it means that consumer wearables are reliable when it comes to the mentioned areas. Facility HRV shows moderate accuracy of (78 per cent) which is a result of motion artifact and limitation of sampling. The smallest agreement (62%) is observed in blood pressure estimation, which indicates the existing technological drawbacks of cuffless BP monitoring sources. In general, the chart shows that wearables are very stable when it comes to the core metrics, but the advanced cardiovascular parameters are yet to be improved.

AI Model AUC Performance



Figure 4: **AI Model AUC Performance**

The above comparison of CNN, LSTM, Random Forest, XGBoost, and Hybrid models were compared in Figure 4 shown above. The line chart shows five AI models with the performance measured by the AUC (Area Under the Curve) scores, and the comparative performance. CNN model has high AUC of 0.92, which means that it is highly accurate with regard to waveform-related tasks like arrhythmia detection. LSTM is slightly underperforming (0.87), which means that it is strong at time-series analysis, but is sensitive to the noise of the data. Random Forest has the minimal AUC (0.83), which indicates that it may not be able to respond to deep physiological trends. XGBoost is better than this with AUC of 0.88, and best overall with 0.93 AUC (Hybrid Model): a combination of wearable and clinical attributes can be much more useful.

Conclusion

The combination of serviceable clothing and the customer wearables.artificial intelligence is one of the new shifts in cardiovascular risk assessment. The review indicates that wearable devices offer consistent, real-time physiological information, especially, when it comes to the heart rate, activity patterns, sleep measurements, and arrhythmia notifications. All these data streams, combined with AI-based analytics, will allow discovering abnormalities in cardiovascular fields in an early stage, performing better risk stratification, and managing it. Even though AI model has a good predictive practice in various cardiovascular outcomes, there are still difficulties associated with the variability of data, bias in algorithm, lack of clinical validation, and unreliable prediction of certain parameters, including blood pressure and HRV. Strong regulation systems, uniform signal-processing methods and the increased interoperability with clinical systems would be necessary lead to wider adoption. In general, wearable-AI systems are promising to change the paradigm of cardiovascular care toward preventive rather than reactive and personalized care.

References

1. **World Health Organization.** (2023). *Cardiovascular Diseases (CVDs)*. Geneva: World Health Organization.
2. **D'Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B.** (2008). General cardiovascular risk profile for use in primary care: The Framingham Heart Study. *Circulation*, **117**(6), 743–753.
3. **Shcherbina, A., Mattsson, C. M., Waggott, D., Salisbury, H., Christle, J. W., Hastie, T., & Ashley, E. A.** (2017). Accuracy in wrist-worn, sensor-based measurements of heart rate and energy expenditure in a diverse cohort. *npj Digital Medicine*, **3**, 1–10.
4. **Perez, M. V., Mahaffey, K. W., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., et al.** (2019). Large-scale assessment of a smartwatch to identify atrial fibrillation. *New England Journal of Medicine*, **381**, 1909–1917.
5. **Johnson, K. W., Torres Soto, J., Glicksberg, B. S., Shameer, K., Miotto, R., Ali, M., et al.** (2018). Artificial intelligence in cardiology. *Nature Medicine*, **24**, 1586–1597.
6. **Attia, Z. I., Noseworthy, P. A., Lopez-Jimenez, F., Asirvatham, S. J., Deshmukh, A. J., Gersh, B. J., et al.** (2019). An artificial intelligence–enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: A retrospective analysis of outcome prediction. *The Lancet*, **394**, 861–867.
7. **Bogo, G., Benzaquen, J. S., Dousty, F., Pedrini, A., & Asteggiano, R.** (2022). Wearable devices for cardiovascular monitoring: Review and critical analysis. *Frontiers in Cardiovascular Medicine*, **9**, 1–12.
8. **Ribeiro, M. T., Singh, S., & Guestrin, C.** (2016). "Why should I trust you?": Explaining the predictions of any classifier. In *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD)* (pp. 1135–1144). ACM.
9. **Sajeev, J. K., Koshy, A. N., Teh, A. W., & Dewey, H. M.** (2021). Wearable devices in cardiology: Current evidence and future directions. *Heart*, **107**(4), 290–296.
10. **Mukkamala, R., Hahn, J. O., Inan, O. T., Mestha, L. K., Kim, C. S., Töreyin, H., & Kyal, S.** (2015). Toward ubiquitous blood pressure monitoring via pulse transit time: Theory and practice. *IEEE Reviews in Biomedical Engineering*, **8**, 55–70.
11. **Steinhubl, S. R., Muse, E. D., & Topol, E. J.** (2015). The emerging field of mobile health. *Science Translational Medicine*, **7**(283), 283rv3.